Siponimod (Mayzent) has been approved on the NHS as the first ever oral treatment for people living with active secondary progressive MS (SPMS) in England and Wales. The drug was recommended for use in Scotland a few days ago, and we expect a decision to follow in Northern Ireland in the coming months.
Siponimod (Mayzent) has been approved by the Scottish Medicine Consortium (SMC) for people with active secondary progressive multiple sclerosis (SPMS), meaning those who experience relapses or have evidence of inflammation on MRI scans.
Earlier this year we renewed our commitment to equality, diversity and inclusion, in recognition of the recent protests and Black Lives Matter movement. As part of that commitment, this October we are marking UK Black History Month for the first time.
The results from our Phase 2a clinical trial have shown that bexarotene is capable of regenerating lost myelin – the protective coating that surrounds nerve fibres, which is damaged in MS. Now, a new trial of the diabetes drug metformin will build on this work.
A group of leading neurologists in childhood MS have agreed that children with multiple sclerosis are not a high risk group for coronavirus. And that almost all children should return to school full time.
Women with MS often report fewer symptoms during pregnancy. But studies exploring whether becoming pregnant or having children affects whether or when someone develops MS have so far been inconclusive. Now, the biggest study yet suggests pregnancy may be linked to a delay in experiencing one of the early signs of MS.
Findings from a UK survey show that during the early phase of the pandemic, when strict lockdown measures were taken, people with MS had a similar chance of getting coronavirus to the general population. The data reinforces that self-isolating greatly decreased the risk of coronavirus.
A committee in the House of Lords is investigating some of the long term impacts of the COVID-19 pandemic. It wants to hear from a wide range of people before making recommendations to the UK government.